Limits...
Overexpression of runt-related transcription factor-2 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer.

Li W, Xu S, Lin S, Zhao W - J. Biomed. Biotechnol. (2012)

Bottom Line: In addition, the nuclear labeling index (LI) of RUNX2 in tumor cells was significantly associated with the advanced clinical stage of EOC tissues (P = 0.001).Especially, subgroup analysis revealed that EOC patients with high clinical stages (III~IV) in high RUNX2 expression group demonstrated a significantly worse clinical outcome than those in low RUNX2 expression group, but patients with low clinical stages (I~II) had no significantly different prognosis between high and low RUNX2 expression groups.Our data suggest for the first time that RUNX2 overexpression is associated with advanced tumor progression and poor clinical outcome of EOC patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Gynaecology and Obstetrics, Clinical Section, PLA General Hospital, Beijing 100853, China.

ABSTRACT

Aim: To investigate clinical significance of runt-related transcription factor (RUNX)-2 in epithelial ovarian cancer (EOC).

Methods: RUNX2 protein expression and its subcellular localization were detected by immunohistochemistry in 116 patients with EOC.

Results: RUNX2 protein was predominantly expressed in cell nucleus of EOC tissues. The expression level of RUNX2 in EOC tissues was significantly higher than that in normal ovarian tissues (P < 0.001). In addition, the nuclear labeling index (LI) of RUNX2 in tumor cells was significantly associated with the advanced clinical stage of EOC tissues (P = 0.001). Moreover, EOC patients with high RUNX2 LI had significantly shorter overall (P < 0.001) and progression-free (P = 0.002) survival than those with low RUNX2 LI. Especially, subgroup analysis revealed that EOC patients with high clinical stages (III~IV) in high RUNX2 expression group demonstrated a significantly worse clinical outcome than those in low RUNX2 expression group, but patients with low clinical stages (I~II) had no significantly different prognosis between high and low RUNX2 expression groups.

Conclusions: Our data suggest for the first time that RUNX2 overexpression is associated with advanced tumor progression and poor clinical outcome of EOC patients. RUNX2 might be a novel prognostic marker of EOC.

Show MeSH

Related in: MedlinePlus

Kaplan-Meier overall (a and c) and progression-free (b and d) survival curves for epithelial ovarian cancer patients with different clinical stages. Subgroup analyses according to clinical stage revealed that epithelial ovarian cancer patients with high clinical stages (III~IV) in high RUNX2 expression group demonstrated a significantly worse clinical outcome than those in low RUNX2 expression group (a and b), but patients with low clinical stages (I~II) had no significantly different prognosis between high and low RUNX2 expression groups (c and d).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3475129&req=5

fig3: Kaplan-Meier overall (a and c) and progression-free (b and d) survival curves for epithelial ovarian cancer patients with different clinical stages. Subgroup analyses according to clinical stage revealed that epithelial ovarian cancer patients with high clinical stages (III~IV) in high RUNX2 expression group demonstrated a significantly worse clinical outcome than those in low RUNX2 expression group (a and b), but patients with low clinical stages (I~II) had no significantly different prognosis between high and low RUNX2 expression groups (c and d).

Mentions: Interestingly, subgroup analyses according to clinical stage revealed that EOC patients with high clinical stages (III~IV) in high RUNX2 expression group demonstrated a significantly worse clinical outcome than those in low RUNX2 expression group (Figures 3(a) and 3(b)), but patients with low clinical stages (I~II) had no significantly different prognosis between high and low RUNX2 expression groups (Figures 3(c) and 3(d)).


Overexpression of runt-related transcription factor-2 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer.

Li W, Xu S, Lin S, Zhao W - J. Biomed. Biotechnol. (2012)

Kaplan-Meier overall (a and c) and progression-free (b and d) survival curves for epithelial ovarian cancer patients with different clinical stages. Subgroup analyses according to clinical stage revealed that epithelial ovarian cancer patients with high clinical stages (III~IV) in high RUNX2 expression group demonstrated a significantly worse clinical outcome than those in low RUNX2 expression group (a and b), but patients with low clinical stages (I~II) had no significantly different prognosis between high and low RUNX2 expression groups (c and d).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3475129&req=5

fig3: Kaplan-Meier overall (a and c) and progression-free (b and d) survival curves for epithelial ovarian cancer patients with different clinical stages. Subgroup analyses according to clinical stage revealed that epithelial ovarian cancer patients with high clinical stages (III~IV) in high RUNX2 expression group demonstrated a significantly worse clinical outcome than those in low RUNX2 expression group (a and b), but patients with low clinical stages (I~II) had no significantly different prognosis between high and low RUNX2 expression groups (c and d).
Mentions: Interestingly, subgroup analyses according to clinical stage revealed that EOC patients with high clinical stages (III~IV) in high RUNX2 expression group demonstrated a significantly worse clinical outcome than those in low RUNX2 expression group (Figures 3(a) and 3(b)), but patients with low clinical stages (I~II) had no significantly different prognosis between high and low RUNX2 expression groups (Figures 3(c) and 3(d)).

Bottom Line: In addition, the nuclear labeling index (LI) of RUNX2 in tumor cells was significantly associated with the advanced clinical stage of EOC tissues (P = 0.001).Especially, subgroup analysis revealed that EOC patients with high clinical stages (III~IV) in high RUNX2 expression group demonstrated a significantly worse clinical outcome than those in low RUNX2 expression group, but patients with low clinical stages (I~II) had no significantly different prognosis between high and low RUNX2 expression groups.Our data suggest for the first time that RUNX2 overexpression is associated with advanced tumor progression and poor clinical outcome of EOC patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Gynaecology and Obstetrics, Clinical Section, PLA General Hospital, Beijing 100853, China.

ABSTRACT

Aim: To investigate clinical significance of runt-related transcription factor (RUNX)-2 in epithelial ovarian cancer (EOC).

Methods: RUNX2 protein expression and its subcellular localization were detected by immunohistochemistry in 116 patients with EOC.

Results: RUNX2 protein was predominantly expressed in cell nucleus of EOC tissues. The expression level of RUNX2 in EOC tissues was significantly higher than that in normal ovarian tissues (P < 0.001). In addition, the nuclear labeling index (LI) of RUNX2 in tumor cells was significantly associated with the advanced clinical stage of EOC tissues (P = 0.001). Moreover, EOC patients with high RUNX2 LI had significantly shorter overall (P < 0.001) and progression-free (P = 0.002) survival than those with low RUNX2 LI. Especially, subgroup analysis revealed that EOC patients with high clinical stages (III~IV) in high RUNX2 expression group demonstrated a significantly worse clinical outcome than those in low RUNX2 expression group, but patients with low clinical stages (I~II) had no significantly different prognosis between high and low RUNX2 expression groups.

Conclusions: Our data suggest for the first time that RUNX2 overexpression is associated with advanced tumor progression and poor clinical outcome of EOC patients. RUNX2 might be a novel prognostic marker of EOC.

Show MeSH
Related in: MedlinePlus